ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial Protocol

INTRODUCTION

  • Org Study ID: IRB00392063
  • Secondary ID: N/A
  • NCT ID: NCT05905276
  • Sponsor: Johns Hopkins University

BRIEF SUMMARY

This is a single-center, randomized-controlled trial to investigate the effectiveness of an ERAS protocol compared to usual care in patients with bladder cancer undergoing ambulatory TURBT. The ERAS protocol is comprised of pre, intra and postoperative components designed to optimize each phase of perioperative care.

  • Overall Status
    Completed
  • Start Date
    December 3, 2023
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
* Patients with suspected or known bladder cancer

- * Age >= 18 years

- * Undergoing initial or repeat TURBT

- * Ambulatory TURBT with same day discharge home planned
Exclusion Criteria:
* Undergoing a planned concomitant procedure

- * Inability to consent for themselves

- * Unable to complete telephone-based follow up after discharge home

- * Undergoing active treatment for muscle-invasive bladder cancer

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Michael E Rezaee, MD, MPH

Role: Principal Investigator

Affiliation: Johns Hopkins University

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact